Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
The main objective of the study is to show that the combination of imatinib mesylate (GLIVEC) and hydroxyurea is superior to hydroxyurea alone in prolonging progression free survival (PFS) of patients...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
The primary objective of this study is to confirm the long-term safety and tolerability of canakinumab 150 mg subcutaneously (s.c) compared to triamcinolone acetonide 40 mg intramuscularly (i.m).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Safety and efficacy study in patients with moderate to severe nail psoriasis
To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe psoriasis affecting the nails as assessed by NAPSI at Week 16
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 12-week treatment, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy of the valsartan/simvastatin combinations 160/20mg up titrated to 320/20mg versus 160/40mg up titrated to 320/40mg in patients with both essential hypertension and hypercholesterolemia
To demonstrate that the combination of valsartan 160mg/simvastatin 40mg has superior efficacy compared to the combination of valsartan 160mg/simvastatin 20mg in the percentage change from baseline to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, multicentre, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatment of lupus nephritis
The primary objective is to explore in non-inferior efficacy of Myfortic administered at a dose of 2160mg/day in combination with reduced corticosteroid regimen compared to the combination with a sta...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Efficacy and safety of SAF312 in patients with urinary incontinence (malfunctioning bladder) due to spinal cord injury
Assessment of the change in maximum cystometric capacity (MCC) following one week of treatment versus baseline
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 1-week, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel trial of lumiracoxib (400 mg od) in patients with acute flares of gout, using indomethacin (50 mg tid) as a comparator
The primary objective of this study is to demonstrate that lumiracoxib 400 mg od is not inferior to indomethacin 50 mg tid in the treatment of acute gout with respect to the mean change from baseline ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy
The primary objective of this study is: • To determine the target dose of canakinumab that leads to at least comparable efficacy as colchicine with respect to the mean number of gout flares occurring ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole
To compare the combination treatment of everolimus and exemestane to exemestane alone with respect to progression-free survival in postmenopausal women with estrogen receptor positive breast cancer re...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)
The primary objective is to compare the overall survival (OS) of patients receiving ASA404 or placebo in combination with paclitaxel and carboplatin for first-line treatment of stage IIIb/IV NSCLC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant